2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Bioinformatics, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Immune Mechanism, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, ALL, B Cell Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

3315 Impact of elevated body mass index on the efficacy of blinatumomab in relapse refractory B-cell precursor acute lymphoblastic leukemia

Sikai Cheng, PharmD, Jose Tinajero, PharmD2, Tamer Othman, MD3, Vaibhav Agrawal, MD4, Hoda Pourhassan, MD5, Dat Ngo, PharmD6, Yazeed Samara, MD7, Amanda Blackmon, DO8, Lindsey A. Murphy, MD, MSCS9, Paul Koller, MD10, Stephen J. Forman, MD11, Anthony Selwyn Stein, MD12, Guido Marcucci, MD13, Vinod Pullarkat, MD14, Ibrahim Aldoss, MD15
1 City of Hope, Duarte, California, United States
2 City of Hope, Duarte, California, United States
3 City of Hope, Duarte, California, United States
4 City of Hope, Duarte, California, United States
5 City of Hope, Duarte, California, United States
6 City of Hope, Duarte, California, United States
7 City of Hope, Duarte, California, United States
8 City of Hope, Duarte, California, United States
9 City of Hope, Duarte, California, United States
10 City of Hope, Duarte, California, United States
11 City of Hope, Duarte, California, United States
12 City of Hope, Duarte, California, United States
13 City of Hope, Duarte, California, United States
14 City of Hope, Duarte, California, United States
15 City of Hope, Duarte, California, United States

Blinatumomab (blina), a CD19xCD3 bispecific T-cell engager (BiTE), is approved across multiple treatment settings for patients (pts) with B-cell ALL (B-ALL), including relapsed/refractory (R/R) disease, measurable residual disease (MRD) positive disease, and as consolidation therapy for pts in in MRD- negative remission. Initially, blina was approved as a fixed-dose regardless of weight. However, the FDA subsequently approved Body Surface Area based dosing for pts under 45 kg.

Emerging evidence suggests that body mass index (BMI) may influence treatment toxicity and outcomes in ALL. Obesity is associated with a higher rate of MRD-positivity post induction therapy in pediatric ALL (Orgel et al; Blood. 2014). Additionally, elevated BMI was associated with poorer outcomes in pts treated on CALGB10403 (Stock et al; Blood 2019). Experience from myeloma and lymphoma showed mixed results on the influence of obesity on cellular and bi-specific therapy. Given the rising prevalence of obesity and the expanding use of blina in a variety of treatment settings, the relationship between high BMI and blina outcomes in R/R ALL remains unclear. Herein, we describe a single center retrospective analysis evaluating the impact of BMI on the clinical outcomes of blina.

We retrospectively reviewed consecutive adult pts (aged 18 years or older) who received blina for the treatment of R/R B-ALL at our center. The primary endpoint was composite CR rates defined as pts achieving complete remission (CR) + CR without hematological recovery (CRi). Secondary endpoints were overall survival (OS), MRD negativity in responders, proportion of pts who underwent subsequent allogeneic transplant (alloHCT). Relapse rate and key safety endpoints such as cytokine release syndrome (CRS), neurotoxicity (NT), and dose interruption to blina were collected. Obesity was defined as BMI > 30.

Of the 137 pts treated with blina for R/R disease, 50 pts (36.5%) were classified as obese. Baseline demographic variables and disease characteristics were generally comparable such as median age (42 vs 34.5 years, p=0.35), male sex (65.5% vs 62%, p=0.68), and receipt of cytoreductive therapy prior to blina (44% vs 39.1%, p=0.57). Compared to non-obese pts, obese pts were more likely to have Ph-like ALL (54% vs 31%, p=0.008), and to be Hispanic (86% vs 64.3%, p=0.006). Obese pts had lower median bone marrow blast at baseline (50 vs 70.4%, p=0.02) and fewer prior lines of therapy (1 vs 2, p=0.04). The median BMI and weight (kg) at baseline between the obese and non-obese pts were; 34.3 vs 25, p<0.01 and 99.2 vs 71, p<0.01 respectively.

There were no statistically significant differences in treatment efficacy. The CR/CRi rate was similar in obese and non-obese pts (66% vs. 65.5%, p=0.97). among responders, rates of MRD negativity were also comparable (90% vs. 85%, p=0.59). Approximately half of the responders in each cohort subsequently underwent alloHCT (46.7% vs. 50%, p=0.77). 1-year cumulative incidence of relapse was not significant (34% vs 27%, p=0.5). The median OS (95% CI) was 21.1 (12.2 – Not Reached) months in the non-obese arm compared to 11.4 (8.3 – 21.6) months in the obese arm, p=0.5.

Treatment-related toxicity was also generally comparable. The incidence of all grade NT was numerically lower in obese pts (4% vs.13.8% vs 4% p=0.06), while the incidence of all grade CRS was not statistically different between obese and non-obese pts (70% vs. 57.5%, p=0.14). Grade 3 or higher CRS or NT were infrequent; CRS (1.1% vs 2%) and NT (1.1% vs 0%).  The rate of blinatumomab dose interruption was similar between the 2 cohorts (11.5% vs 14% p=0.66.) There were 9 pts with BMI > 40, in which most were Hispanic (88.9%), had ph-like genetics (77.8%), and males (77.8%). Response to blina (66.7%) was observed but almost all relapsed (83.3%). All grade CRS (66.6%) was common with no observed NT (0%) in this small cohort.

Although obesity, as defined by BMI, has been associated with inferior outcomes with conventional ALL therapy, our analysis did not demonstrate a significant impact of obesity on the efficacy or toxicity of blinatumomab in pts with R/R B-ALL. Obesity was more frequently observed in pts of Hispanic background and ph-like genetics. These findings support blinatumomab as a safe and effective treatment option regardless of BMI and suggest that immunotherapy-based approaches may help mitigate the adverse prognostic impact historically observed with obesity in ALL.

Sikai Cheng, PharmD: No relevant conflicts of interest to declare.